Inventor · disambiguated record
Ren Zhi Cai
Also filed as: CAI REN Z · CAI REN ZHI
10 granted patents·3 pending applications·194 citations·filing 1985–2018
90Inventor score
Files withUNIV MIAMI4SCHALLY ANDREW VICTOR3UNIV TULANE3SCHALLY ANDREW2ADMINISTRARE S OF THE TULANE E1
Top patents by PatentIndex Score
13 records- 0191US4650787ABiologically active octapeptidesSCHALLY ANDREW VICTOR·Filed 1985·Granted Mar 17, 1987·90 cites·16 claims
- 0286US8691942B2N- and C- terminal substituted antagonistic analogs of GH-RHSCHALLY ANDREW VICTOR·Filed 2010·Granted Apr 8, 2014·5 cites·9 claims
- 0381US5843903ATargeted cytotoxic anthracycline analogsUNIV TULANE·Filed 1995·Granted Dec 1, 1998·36 cites·27 claims
- 0480US9260504B2N- and C-terminal substituted antagonistic analogs of GH-RHUNIV MIAMI·Filed 2014·Granted Feb 16, 2016·2 cites·5 claims
- 0579US9079974B2GH-RH analogs with potent agonistic effectsSCHALLY ANDREW VICTOR·Filed 2011·Granted Jul 14, 2015·4 cites·15 claims
- 0678US8227421B2Fluorinated GHRH antagonistsSCHALLY ANDREW·Filed 2009·Granted Jul 24, 2012·5 cites·19 claims
- 0778US4725577ABiologically active lysine containing octapeptidesUNIV TULANE·Filed 1986·Granted Feb 16, 1988·36 cites·15 claims
- 0877US8227405B2Fluorinated GHRH antagonistsSCHALLY ANDREW·Filed 2009·Granted Jul 24, 2012·4 cites·1 claims
- 0976US7452865B2Antagonistic analogs of GH RH (2003)ADMINISTRARE S OF THE TULANE E·Filed 2004·Granted Nov 18, 2008·7 cites·11 claims
- 1057US2016166652A1Novel n- and c-terminal substituted antagonistic analogs of gh-rhUNIV MIAMI·Filed 2015·Application pending·0 cites
- 1150US6184374B1Targeted cytotoxic anthracycline analogsUNIV TULANE·Filed 1998·Granted Feb 6, 2001·5 cites·5 claims
- 1250US2020276273A1Method for treating myeloid leukemiaUNIV MIAMI·Filed 2018·Application pending·0 cites
- 1341US2015274798A1Novel gh-rh analogs with potent agonistic effectsUNIV MIAMI·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ren Zhi Cai files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →